15 June 2020 - Anjeso is the only approved 24  hour, intravenous COX-2 preferential NSAID that offers once-daily dosing.

Baudax Bio today announced the commercial launch of Anjeso (meloxicam) injection. Anjeso was approved by the U.S. FDA on 20 February 2020.

Baudax also announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through status and established a new reimbursement code for Anjeso. The code, C9059, is scheduled to become effective July 1, 2020.